Church lab spin-out raises $60 million

GRO Biosciences, a start-up cofounded by Harvard geneticist George Church in 2016, has raised another $60 million in venture funding. GRObio is developing protein therapeutics using synthetic amino acids that go beyond the 20 standard building blocks found in human biology, with the hope of treating autoimmune and other diseases. The new money will be put toward human trials of a drug candidate for refractory gout.